Cardio Diagnostics Holdings CDIO

NASDAQ CDIO

$2.07 +0.12 (+6.15%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Market Cap6.04 Mn

P/E-0.93

P/S417.81

Div. Yield0.00

Revenue Growth (1y) (Qtr)-28.29

Add ratio to table…

About

Cardio Diagnostics Holdings, Inc. is a medical technology company that develops and commercializes AI driven multi omics based diagnostic tests for cardiovascular disease. The company was formed to advance prevention, early detection and treatment of conditions such as coronary heart disease, stroke, heart failure and diabetes by leveraging its proprietary AI driven multi omics engine. Its mission is to provide every American adult with insight into their individual risk for cardiovascular disease and to shift the care model from reactive to proactive. Cardio Diagnostics Holdings, Inc. aims to become a leading medical technology company enabling improved prevention, detection and management of cardiovascular disease.

The company generates revenue primarily from the sale of its clinical tests such as Epi+Gen CHD and PrecisionCHD and its software platforms including HeartRisk and CardioInnovate360 to health care providers, health systems, employers and payors. It also pursues reimbursement through CPT PLA codes and works with commercial and government payors to achieve broader coverage. Additionally, the company offers laboratory services via its CLIA certified high complexity testing laboratory and provides research use only kits under the CardioInnovate360 brand to support biopharmaceutical development.

Cardio Diagnostics Holdings, Inc. positions itself as a pioneer in epigenetics based cardiovascular diagnostics, claiming to be the first company to bring epigenetics driven clinical tests to market. Its main competitors include traditional lipid based risk assessment tools such as the Framingham Risk Score and the ASCVD Pooled Cohort Equation, imaging modalities like coronary artery calcium scoring and stress echocardiogram, and proteomic assays. According to Research and Markets, the global cardiovascular diagnostic testing market is projected to grow from 8.47 billion dollars in 2022 to 12.41 billion dollars by 2027 reflecting a compound annual growth rate of 7.94 percent. The company’s tests have demonstrated superior sensitivity compared to conventional methods; for example, Epi+Gen CHD showed 76 percent sensitivity in men and 78 percent in women versus 44 percent and 32 percent for the Framingham Risk Score and ASCVD Pooled Cohort Equation. PrecisionCHD demonstrated 80 percent sensitivity in men and 76 percent in women exceeding the 58 percent sensitivity of exercise electrocardiogram. These performance advantages are supported by peer reviewed studies conducted with institutions such as Intermountain Healthcare and the University of Iowa Hospitals and Clinics. Cardio Diagnostics Holdings, Inc. benefits from a robust intellectual property portfolio that includes multiple patent families covering its AI driven multi omics engine and related biomarker discoveries. The proprietary AI driven multi omics engine enables rapid identification of genetic and epigenetic markers and their translation into clinical assays, providing a scalable platform for future product development. Furthermore, the dynamic nature of epigenetic biomarkers allows the tests to reflect changes in lifestyle and intervention, offering potential to monitor treatment effectiveness and personalize patient care.

The company serves physicians, hospitals, health systems, employers, payors and patients. Specific collaborators mentioned in the filing include Intermountain Healthcare, University of Iowa Hospitals and Clinics, the YMCA of East Tennessee and the Southdale YMCA. Additionally, Cardio Diagnostics Holdings, Inc. targets self insured employers, group purchasing organizations, life insurers and telemedicine providers as part of its commercial outreach. The firm also works with primary care clinics and concierge medicine practices to increase adoption of its tests among patients who seek preventive health services.

Investment Thesis

▲ Bull case

Cardio Diagnostics’ expansion into the Indian market through its strategic partnership with Aimil and Dr. Lal PathLabs represents a significant and underappreciated growth catalyst that could substantially accelerate revenue diversification and market penetration beyond the U.S. The partnership leverages Dr. Lal PathLabs’ extensive network of 290+ clinical laboratories and 300+ MD pathologists, providing immediate access to a vast patient base in a country where cardiovascular disease prevalence reaches up to 13% in urban areas and 7.4% in rural regions. Given that India accounts for nearly one-fifth of the global population and bears a disproportionate burden of cardiovascular mortality, the addressable market for PrecisionCHD™ is immense. The company’s ability to detect non-obstructive coronary heart disease — including conditions like Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) — which are frequently missed by standard angiograms, gives it a distinct diagnostic advantage in a market where early and accurate detection is critically needed. With commercial rollout expected in 2026, this international expansion could unlock a new, high-growth revenue stream that is not yet reflected in current market expectations, particularly as the company begins to scale beyond its U.S.-centric operations. The partnership also validates the clinical and technological credibility of PrecisionCHD™ in a rigorous, regulated healthcare environment, which could facilitate future expansions into other emerging markets with similar unmet needs.
The company’s growing integration into employer-sponsored wellness programs — evidenced by its presence at national benefits conferences and partnerships with entities like the Southdale YMCA — reveals a powerful, under-the-radar pathway to scalable adoption that targets the root cost drivers of cardiovascular disease in the U.S. healthcare system. By positioning its Epi+Gen CHD™ and PrecisionCHD™ tests as tools for employers, unions, and brokers to reduce both direct medical costs and indirect costs like absenteeism and lost productivity, Cardio Diagnotics is tapping into a massive economic incentive: cardiovascular disease remains a leading driver of healthcare expenditures, with up to 80% of cases being preventable per the World Heart Federation. The ability to identify at-risk individuals even when traditional biomarkers like cholesterol and blood pressure appear normal gives the company a unique edge in preventive care, enabling early intervention that can avert costly cardiac events. These community and employer-based initiatives are not merely altruistic outreach; they represent a deliberate, high-leverage strategy to embed its tests into population health management frameworks, where reimbursement and adoption are increasingly tied to outcomes and cost savings. As employers and health plans face mounting pressure to demonstrate value and control expenses, Cardio Diagnostics’ value proposition — reducing spend while improving population health — becomes increasingly compelling, potentially accelerating reimbursement pathways and institutional adoption in ways that are not yet fully priced into the stock.
The upcoming investor call on February 19, 2026, serves as a critical inflection point where the company may unveil concrete progress on reimbursement advancements and commercial traction that the market has been overly skeptical about, creating a potential for a meaningful re-rating. Despite the absence of a recent earnings call, the company’s consistent flow of strategic announcements — including international expansion, community partnerships, and conference participation — suggests ongoing operational momentum that is not being adequately rewarded by investors. The call will provide updates on commercially available tests, recent breakthrough clinical data, and strategic growth initiatives, offering a platform to clarify monetization pathways, particularly around CPT code attainment and payer negotiations, which are often opaque to outside observers. Given that the company’s core technology combines epigenetics, genetics, and AI to deliver actionable insights beyond standard lipid panels, successful reimbursement validation could unlock broader clinical adoption and shift the perception of its tests from niche innovations to standard-of-care tools in cardiovascular risk assessment. If management demonstrates tangible progress in securing coverage from major health plans or demonstrates strong early adoption metrics from partnerships like those with Dr. Lal PathLabs or YMCA networks, the market may begin to reassess the company’s path to profitability and scalability, especially given the large, growing, and underpenetrated market for precision cardiovascular diagnostics.

Cardio Diagnostics’ expansion into the Indian market through its strategic partnership with Aimil and Dr. Lal PathLabs represents a significant and underappreciated growth catalyst that could substantially accelerate revenue diversification and market penetration beyond the U.S. The partnership leverages Dr. Lal PathLabs’ extensive network of 290+ clinical laboratories and 300+ MD pathologists, providing immediate access to a vast patient base in a country where cardiovascular disease prevalence reaches up to 13% in urban areas and 7.4% in rural regions. Given that India accounts for nearly one-fifth of the global population and bears a disproportionate burden of cardiovascular mortality, the addressable market for PrecisionCHD™ is immense. The company’s ability to detect non-obstructive coronary heart disease — including conditions like Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) — which are frequently missed by standard angiograms, gives it a distinct diagnostic advantage in a market where early and accurate detection is critically needed. With commercial rollout expected in 2026, this international expansion could unlock a new, high-growth revenue stream that is not yet reflected in current market expectations, particularly as the company begins to scale beyond its U.S.-centric operations. The partnership also validates the clinical and technological credibility of PrecisionCHD™ in a rigorous, regulated healthcare environment, which could facilitate future expansions into other emerging markets with similar unmet needs.
The company’s growing integration into employer-sponsored wellness programs — evidenced by its presence at national benefits conferences and partnerships with entities like the Southdale YMCA — reveals a powerful, under-the-radar pathway to scalable adoption that targets the root cost drivers of cardiovascular disease in the U.S. healthcare system. By positioning its Epi+Gen CHD™ and PrecisionCHD™ tests as tools for employers, unions, and brokers to reduce both direct medical costs and indirect costs like absenteeism and lost productivity, Cardio Diagnotics is tapping into a massive economic incentive: cardiovascular disease remains a leading driver of healthcare expenditures, with up to 80% of cases being preventable per the World Heart Federation. The ability to identify at-risk individuals even when traditional biomarkers like cholesterol and blood pressure appear normal gives the company a unique edge in preventive care, enabling early intervention that can avert costly cardiac events. These community and employer-based initiatives are not merely altruistic outreach; they represent a deliberate, high-leverage strategy to embed its tests into population health management frameworks, where reimbursement and adoption are increasingly tied to outcomes and cost savings. As employers and health plans face mounting pressure to demonstrate value and control expenses, Cardio Diagnostics’ value proposition — reducing spend while improving population health — becomes increasingly compelling, potentially accelerating reimbursement pathways and institutional adoption in ways that are not yet fully priced into the stock.
The upcoming investor call on February 19, 2026, serves as a critical inflection point where the company may unveil concrete progress on reimbursement advancements and commercial traction that the market has been overly skeptical about, creating a potential for a meaningful re-rating. Despite the absence of a recent earnings call, the company’s consistent flow of strategic announcements — including international expansion, community partnerships, and conference participation — suggests ongoing operational momentum that is not being adequately rewarded by investors. The call will provide updates on commercially available tests, recent breakthrough clinical data, and strategic growth initiatives, offering a platform to clarify monetization pathways, particularly around CPT code attainment and payer negotiations, which are often opaque to outside observers. Given that the company’s core technology combines epigenetics, genetics, and AI to deliver actionable insights beyond standard lipid panels, successful reimbursement validation could unlock broader clinical adoption and shift the perception of its tests from niche innovations to standard-of-care tools in cardiovascular risk assessment. If management demonstrates tangible progress in securing coverage from major health plans or demonstrates strong early adoption metrics from partnerships like those with Dr. Lal PathLabs or YMCA networks, the market may begin to reassess the company’s path to profitability and scalability, especially given the large, growing, and underpenetrated market for precision cardiovascular diagnostics.

▼ Bear case

Despite the promising narrative around its technology, Cardio Diagnostics continues to operate without any meaningful revenue generation or profitability, and the market may be overestimating the near-term commercial viability of its tests in the face of entrenched diagnostic paradigms and reimbursement hurdles. The company has not yet achieved widespread adoption of its Epi+Gen CHD™ or PrecisionCHD™ tests in major U.S. healthcare systems, and there is no evidence in the provided materials of significant sales volumes, recurring revenue streams, or signed contracts with large national health plans or integrated delivery networks. While partnerships with entities like Dr. Lal PathLabs and the Southdale YMCA are encouraging, they remain in early stages — with the India rollout not expected until 2026 and the YMCA initiative limited to localized, community-based events — suggesting that scalable, revenue-generating distribution channels are still nascent. The reliance on telemedicine partners and at-home kits for test distribution, while innovative, introduces complexity in sample collection, patient adherence, and result reporting that could hinder real-world utility and adoption at scale. Without clear, audited financials showing improving top-line traction or gross margins, the market may be assigning value based on futuristic potential rather than current execution, leaving the stock vulnerable to a correction if milestones are delayed or commercialization proves more difficult than anticipated.
The company operates in a highly competitive and regulated diagnostic landscape where established players — including major laboratory corporations and specialized cardiology diagnostics firms — possess far greater resources, established relationships with physicians and payers, and entrenched positions in clinical guidelines, posing a significant barrier to widespread adoption of Cardio Diagnostics’ novel approach. Despite the clinical validity of its tests in detecting non-obstructive forms of coronary artery disease like INOCA and MINOCA, there is no indication that major cardiology societies or clinical practice guidelines have yet endorsed or recommended Epi+Gen CHD™ or PrecisionCHD™ as part of standard risk assessment protocols. Without such endorsement, adoption will remain dependent on individual physician awareness and initiative, which is notoriously slow and fragmented in cardiovascular care. Furthermore, the reimbursement pathway for novel biomarkers is notoriously lengthy and uncertain, with many similar innovations failing to secure adequate coverage despite strong clinical data. The company’s dependence on achieving favorable coverage decisions — as highlighted in its own risk factors — means that even if the tests are clinically superior, commercial success hinges on navigating a complex, slow-moving payer ecosystem that may not prioritize preventive diagnostics over acute care interventions, especially in fee-for-service models that still dominate much of the U.S. healthcare system.
The international expansion into India, while strategically promising, introduces substantial execution risks that the market may be underestimating, including regulatory complexity, pricing sensitivity, and dependence on third-party partners for commercialization. Although the partnership with Dr. Lal PathLabs provides access to a large diagnostic network, success in India will require navigating a fragmented healthcare system with varying state-level regulations, inconsistent reimbursement structures, and significant price sensitivity among both providers and patients. The company’s technology, while innovative, may face challenges in gaining traction in a market where diagnostic decisions are often driven by cost and availability rather than cutting-edge molecular insights, particularly in public health settings or under-resourced clinics. Moreover, the reliance on partners like Aimil for distribution and Dr. Lal PathLabs for laboratory execution introduces dependency risks — any misalignment in commercial incentives, delays in regulatory approvals, or limitations in the partner’s sales and marketing capacity could severely impede rollout timelines. Given that the initial phase is focused on integration and alignment with local protocols, with commercial scale-up not expected until 2026, the contribution from this market to near-term revenue is likely to be minimal, and any delays could further postpone the realization of the growth potential that investors are hoping for, especially if U.S.-based adoption remains sluggish.

Despite the promising narrative around its technology, Cardio Diagnostics continues to operate without any meaningful revenue generation or profitability, and the market may be overestimating the near-term commercial viability of its tests in the face of entrenched diagnostic paradigms and reimbursement hurdles. The company has not yet achieved widespread adoption of its Epi+Gen CHD™ or PrecisionCHD™ tests in major U.S. healthcare systems, and there is no evidence in the provided materials of significant sales volumes, recurring revenue streams, or signed contracts with large national health plans or integrated delivery networks. While partnerships with entities like Dr. Lal PathLabs and the Southdale YMCA are encouraging, they remain in early stages — with the India rollout not expected until 2026 and the YMCA initiative limited to localized, community-based events — suggesting that scalable, revenue-generating distribution channels are still nascent. The reliance on telemedicine partners and at-home kits for test distribution, while innovative, introduces complexity in sample collection, patient adherence, and result reporting that could hinder real-world utility and adoption at scale. Without clear, audited financials showing improving top-line traction or gross margins, the market may be assigning value based on futuristic potential rather than current execution, leaving the stock vulnerable to a correction if milestones are delayed or commercialization proves more difficult than anticipated.
The company operates in a highly competitive and regulated diagnostic landscape where established players — including major laboratory corporations and specialized cardiology diagnostics firms — possess far greater resources, established relationships with physicians and payers, and entrenched positions in clinical guidelines, posing a significant barrier to widespread adoption of Cardio Diagnostics’ novel approach. Despite the clinical validity of its tests in detecting non-obstructive forms of coronary artery disease like INOCA and MINOCA, there is no indication that major cardiology societies or clinical practice guidelines have yet endorsed or recommended Epi+Gen CHD™ or PrecisionCHD™ as part of standard risk assessment protocols. Without such endorsement, adoption will remain dependent on individual physician awareness and initiative, which is notoriously slow and fragmented in cardiovascular care. Furthermore, the reimbursement pathway for novel biomarkers is notoriously lengthy and uncertain, with many similar innovations failing to secure adequate coverage despite strong clinical data. The company’s dependence on achieving favorable coverage decisions — as highlighted in its own risk factors — means that even if the tests are clinically superior, commercial success hinges on navigating a complex, slow-moving payer ecosystem that may not prioritize preventive diagnostics over acute care interventions, especially in fee-for-service models that still dominate much of the U.S. healthcare system.
The international expansion into India, while strategically promising, introduces substantial execution risks that the market may be underestimating, including regulatory complexity, pricing sensitivity, and dependence on third-party partners for commercialization. Although the partnership with Dr. Lal PathLabs provides access to a large diagnostic network, success in India will require navigating a fragmented healthcare system with varying state-level regulations, inconsistent reimbursement structures, and significant price sensitivity among both providers and patients. The company’s technology, while innovative, may face challenges in gaining traction in a market where diagnostic decisions are often driven by cost and availability rather than cutting-edge molecular insights, particularly in public health settings or under-resourced clinics. Moreover, the reliance on partners like Aimil for distribution and Dr. Lal PathLabs for laboratory execution introduces dependency risks — any misalignment in commercial incentives, delays in regulatory approvals, or limitations in the partner’s sales and marketing capacity could severely impede rollout timelines. Given that the initial phase is focused on integration and alignment with local protocols, with commercial scale-up not expected until 2026, the contribution from this market to near-term revenue is likely to be minimal, and any delays could further postpone the realization of the growth potential that investors are hoping for, especially if U.S.-based adoption remains sluggish.

Segments Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Diagnostic Equipment

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	GEHC	GE HealthCare Technologies Inc.	primary	29.54 Bn	14.41	1.39	10.10 Bn
2	LNTH	Lantheus Holdings, Inc.	primary	6.56 Bn	23.84	4.22	0.57 Bn
3	HTFL	Heartflow, Inc.	primary	4.04 Bn	-166.44	19.90	-
4	NEOG	Neogen Corp	primary	2.59 Bn	-365.72	2.98	0.79 Bn
5	BFLY	Butterfly Network, Inc.	primary	1.96 Bn	-26.25	17.52	-
6	CBLL	Ceribell, Inc.	primary	0.93 Bn	-14.07	9.11	0.02 Bn
7	QDEL	QuidelOrtho Corp	primary	0.87 Bn	-	-	2.89 Bn
8	VREX	Varex Imaging Corp	primary	0.78 Bn	34.62	0.90	0.37 Bn

Cardio Diagnostics Holdings CDIO

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password